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Abstract 
Asparaginase-associated pancreatitis is a life-threatening toxicity to childhood acute lymphoblastic 
leukemia treatment. To elucidate genetic predisposition and asparaginase-associated pancreatitis 
pathogenesis, ten acute lymphoblastic leukemia trial groups contributed remission samples from patients 
aged 1.0−17.9 years and treated from 2000−2016. Cases were defined (n=244) by at least two of the 
following criteria: i) abdominal pain, ii) pancreatic enzymes >3 x upper normal limit, iii) imaging compatible 
with asparaginase-associated pancreatitis. Controls (n=1320) completed intended asparaginase therapy, 
78% receiving ≥8 pegylated-asparaginase injections, without developing aparaginase-associated 
pancreatitis. rs62228256 on 20q13.2 showed the strongest association (OR=3.75; P=5.2x10
-8
). Moreover, 
rs13228878 (OR=0.61; P=7.1x10
-6
) and rs10273639 (OR=0.62; P=1.1x10
-5
) on 7q34 showed significant 
association. A Dana Farber Cancer Institute ALL Consortium cohort consisting of patients treated protocols 
from 1987−2004 (controls=285, cases=33), and the Children’s Oncology Group AALL0232 cohort 
(controls=2653, cases=76) were available as replication cohorts for the 20q13.2 and 7q34 variants, 
respectively. While rs62228256 was not validated (P=0.86), both rs13228878 (P=0.03) and rs10273639 
(P=0.04) were. rs13228878 and rs10273639 are in high linkage disequilibrium (r
2
=0.94) and associated with 
elevated expression of the trypsinogen encoding PRSS1 gene and are known risk variants for alcohol-
associated and sporadic pancreatitis in adults. Intra-pancreatic trypsinogen cleavage to proteolytic trypsin 
induces autodigestion and pancreatitis. Asparaginase-associated pancreatitis and non-asparaginase 
associated pancreatitis shares genetic predisposition and targeting the trypsinogen activation pathway may 
enable identification of effective interventions towards asparaginase-associated pancreatitis. 
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Introduction 
Intensification of chemotherapy has generated 5-year survival rates of childhood acute lymphoblastic 
leukemia (ALL) above 90%, but therapy-related toxicity has similarly increased
1
. Asparaginase is a key drug 
in childhood ALL therapy and is gaining interest as an anti-metastatic agent in breast cancer
2
. It depletes 
the body of the non-essential amino acid asparagine through deamidation of asparagine into aspartic acid 
and ammonia
3
, and targets protein synthesis in malignant lymphoblasts due to impaired asparagine 
synthesizing  ability
4,5
. Pancreatitis associated with asparaginase therapy (AAP) is a frequent toxicity 
affecting 4−10% of children treated on contemporary ALL protocols, and is associated with severe 
complications
6–9
. In addition, re-exposure to  asparaginase after AAP is associated with a high risk (~50%) of 
a second AAP, and thus AAP often entail truncation of asparaginase therapy, thereby decreasing the chance 
of ALL survival
4,5,9
. The pancreatitis-causing mechanism of asparaginase and identification of patients with 
an altered risk of AAP remains elusive
10
. To explore the AAP phenotype and investigate host-genome 
variants associated with risk of AAP, the Ponte di Legno toxicity working group (PTWG) initiated a three-
step AAP study: I) Defining diagnostic consensus criteria for AAP
11
; II) Describing the AAP phenotype in 
patients across multiple ALL trial groups
9
; III) Exploring genotype-phenotype associations in a genome-wide 
approach to identify patients with altered risk of AAP
9,11
. Genome-wide association (GWA) studies are 
agnostic by design, reporting phenotype-genotype associations without prior hypothesis and often 
including a speculative mechanism. Replication of GWA study results are a requisite for credibility. 
Accordingly, this study presents results from the largest AAP GWA study so far, with a strong focus on 
investigating previously validated variants associated with non-asparaginase induced pancreatitis and 
replicating top results in similar childhood ALL cohorts.  
 
Methods 
Study design and participants 
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Ten international childhood ALL trial groups (supplemental table 1) contributed to the discovery cohort. 
Post remission DNA was collected from June 2015 to January 2017, three groups collected DNA on AAP 
cases only while seven groups did so on both cases and controls (supplemental figure 1). The database 
containing phenotype data was approved by the regional ethical review board of The Capital Region of 
Denmark (H-2-2010-022), the Danish Data Protection Authorities (j.nr.: 2012-58-0004), and by relevant 
regulatory authorities in all participating countries. Genotype data was stored at the Technical University of 
Denmark’s server Computerome
12
.  
Children (age 1.0–17.9 years) with newly diagnosed ALL between January 2000 and January 2016 were 
eligible, irrespective of ethnicity. Pancreatitis was defined as asparaginase-associated if diagnosed within 50 
days of the last asparaginase (native E. coli asparaginase or polyethylene glycolated E. coli asparaginase 
(PEG-asparaginase)) injection and cases fulfilled the PTWG consensus definition for AAP: At least two of i) 
amylase, pancreatic amylase, or pancreatic lipase > 3 x upper normal limit (UNL), ii) abdominal pain, iii) 
imaging compatible with AAP. All controls received the planned amount of asparaginase therapy in their 
respective protocols, with more than 78% (1024/1320) receiving at least eight injections of PEG-
asparaginase without developing AAP. A subset of 62 AAP cases has previously been included in a Nordic 
Society of Pediatric Haematology and Oncology (NOPHO) GWA study
13
. These samples were genotyped on 
identical genotyping arrays as the remaining cohort, raw genotyping data on these patients were pooled 
with the remaining cohort prior to quality control, and association analyses were done in one cohort.  
 
Genotyping 
Post remission DNA was genotyped by Aros Applied Biotechnology A/S, Aarhus, Denmark, on an Illumina 
Omni2.5exome-8 BeadChip arrays using the human genome assembly (GRCh37) for reference. Quality 
control was performed using the PLINK tool
14
, and single nucleotide polymorphisms (SNPs) were annotated 
in Ensembl Variant Effect Predictor GCRCh37
15
. Alleles given are refSNP alleles according to dbSNP (not 
necessarily the alleles supplied by the Illumina map)
16
 .  
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Quality control 
Quality control was performed according to previously published criteria
17
 (supplemental figures 2−4), 
excluding individuals with: i) a discordance in  number of X chromosomes between geno- and phenotypes; 
ii) missing data on > 3% of SNPs; iii) excess heterozygosity between autosomal SNPs; iv) high relatedness 
between samples. SNPs were excluded based on: i) missing data on > 2% of individuals (call rate); ii) Hardy 
Weinberg equilibrium; iii) Minor allele frequency < 0.01; iv) Difference in call rate between cases and 
controls (Fisher exact test P < 1.10
-5
); v) Duplicated genomic position.  
 
Replication 
Three top SNPs were tested for validation in two separate cohorts. The Children’s Oncology Group 
AALL0232 ALL cohort included previously genotyped data on PRSS1-2 variants (but not on the NFATC2 
variant). The NFATC2 variant was de novo genotyped in a cohort of patients from the DFCI ALL Consortium 
protocols 87−01, 91−01, 95−01 and 00−01 protocols (1987-2004). The AALL0232 ALL cohort included 76 
cases diagnosed using National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE 
criteria) (supplemental page 6−9), and 2577 controls
8
. The cohort is described in detail in the appendix
8
. 
The AALL0232 cohort was genotyped on the Affymetrix Genome-Wide Human SNP 6.0 Array, and imputed 
genotypes were generated using 1000 Genomes as reference population as reported (ref: PMID 26265699). 
Time-dependent analysis (Cox proportional hazards regression) was performed adjusting for age and 
ancestry. The DFCI ALL Consortium protocols 87−01, 91−01, 95−01 and 00−01 cohort received 20−30 weeks 
of post-induction asparaginase therapy (supplemental page 9−11). Thirty-three cases diagnosed according 
to the CTCAE criteria and 285 controls were included in this cohort, and genotyped by allele-specific 
oligonucleotides (ASOs) hybridization as described elsewhere
18,19
. Pearson’s correlation coefficient was 
used investigation association between genotype and AAP.  
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Statistical analysis 
Association analysis was done in PLINK using logistic regression, assuming an additive genetic model, and 
adjusting for genetic ancestry and age. Genetic ancestry was determined by clustering analysis, and non-
CEU ancestry was defined as individuals > 16 standard deviations away from the HapMap-defined CEU 
(Northern and Western European) centroid mean. Using this model, multidimensional scaling plots showed 
an equal distribution of cases and controls according to ancestry (supplemental figure 3) and QQ plots 
showed no sign of population substructure (λ = 1.02, supplemental figure 4).  Statistical analysis of pheno- 
and genotype associations was performed in the statistical program R version 3.3.3
20
. Linear and logistic 
regression analysis were used for association between genotypes and continuous or categorical clinical 
variables adjusting for age and ancestry. And genotype was treated as a numerical value (0, 1 or 2 minor 
alleles) for additive effect. The Kaplan-Meier method was used to estimate probability of event-free 
survival (pEFS) according to genotypes, and differences were compared with the 2-sided log-rank test. No 
prior sample size calculations were applied for pre-study power calculations. Two-sided p-values below 
0.05 were regarded as significant. SNPs were annotated to genes 10 kb up- or downstream from 
transcription start- and end sites, respectively, and all SNPs with a p-value below 5 x 10
-5
 were manually 
inspected for association to genes and pathways previously associated to pancreatitis.  Investigated SNPs 
were explored using dbSNP
16
 and Ensembl
15
, linkage disequilibrium (LD) between SNPs by the National 
Cancer Institute LDassoc tool
21
, tissue expression (expressive quantitative trait loci (eQTLs)) by GTeX
22
, 
regulatory effect by RegulomeDB
23
, and regional association plots were produced by the LocusZoom tool
24
. 
Genes and SNPs previously associated to pancreatitis were investigated by searching PubMed for reports 
published in English within the last ten years, using the search terms “pancreatitis” AND “genome” OR 
“genetic” OR “genotype” in the title. Gene functions were defined by Genecards
25
 (www.genecards.org).  
 
Results 
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After quality control filtering, 244 cases, 1320 controls and 1401908 SNPs were eligible for association 
analysis. Two hundred and five of 244 (84%) cases and 1185/1320 (90%) of controls were of European 
(CEU) ancestry (supplemental figure 4). Median age was 8.1 [interquartile range {IQR} 4.3 to 13.1] and 5.0 
[IQR: 3.0 to 9.0] years in cases and controls, respectively. Fifty-five percent of both cases (133/244) and 
controls (724/1320) were of male gender.      
Figure 1 shows the significance of SNPs associated to AAP. The variant rs62228256 (reference allele=C, 
minor allele=T {C>T}) on 20q13.2 showed the strongest association to AAP (odds ratio {OR}, 3.75; 95% CI, 
2.33 to 6.04; P=5.2 x 10
-8
). Rs62228256 is located 274 kilobase pairs upstream from Nuclear factor of 
activated T cells (NFATC2) and has been documented to be an eQTL for this gene in pancreatic tissue 
(supplemental figure 5).  
Among the 30 SNPs most associated to AAP with a p-value of 5 x 10
-5
 or lower were rs13228878 (A>G; OR, 
0.61; 95% CI, 0.5 to 0.76; P=7.1 x 10
-6
) and rs10273639 (C>T; OR, 0.62; 95% CI, 0.5 to 0.77; P=1.1 x 10
-5
) 
(table 1). These SNPs reside on the same haplotype and are in high LD (CEU population LD; r
2
=0.94) in the 
PRSS1-PRSS2 locus on chromosome 7 (figure 2).  PRSS1 and PRSS2 encode for the proteases cationic and 
anionic trypsinogen, respectively. Both minor alleles rs13228878_G and rs10273639_T reduce the risk of 
AAP. When performing association analysis in the CEU population of 205 AAP cases and 1185 controls, 
rs62228256 (OR, 3.75; 95% CI, 2.27 to 6.2; P=2.47 x 10
-7
), rs13228878 (OR, 0.60; 95% CI, 0.48 to 0.76; P=2.1 
x 10
-5
) and rs10273639 (OR, 0.62; 95% CI, 0.49 to 0.78; P=3.8 x 10
-5
) (supplemental figures 6−8 and 
supplemental table 2 ) remained strongly associated with AAP. Further investigation of previously validated 
SNPs within genes known to regulate trypsin activation
26
 (supplemental table 3) found AAP associated with 
rs17107315 in pancreatic secretory trypsin inhibitor (SPINK1; OR, 2.87; 95% CI, 1.36 to 5.8; P=4 x 10
-3
), 
rs10436957 in chymotrypsin C (CTRC; OR, 0.69; 95% CI, 0.53 to 0.89; P=5 x 10
-3
) and rs4409525 in Claudin-2 
(CLDN2; OR, 1.41; 95% CI, 1.08 to 1.83; P=0.01) with all minor alleles altering AAP risk in direction and 
effect very similar to what has previously been reported.  
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In a logistic regression model, testing whether the effect of the most associated PRSS1-PRSS2 variant 
(rs13228878) was modified by rs17107315 (SPINK1), rs10436957 (CTRC) and rs4409525 (CLDN2), no 
significant interactions were identified (P=0.48, P=0.95 and P=0.93, respectively).  
Validation of results 
In validating our top SNP in the NFATC2 locus (rs62228256) and top SNPs the PRSS1-PRSS2 locus 
(rs13228878 and rs10273639) we used two cohorts of children with ALL: one treated according to the DFCI 
ALL Consortium 87−01, 91−01, 95−01 and 00−01 protocols
27,28
, and the other according to Children’s 
Oncology Group AALL0232 protocol
8
 (supplemental page 6−12). Whereas the association between AAP and 
rs6228256 genotype was not replicated in DFCI ALL Consortium cohort (P=0.77, supplemental page 10), 
both rs13228878 (hazard ratio, 0.68; 95%CI, 0.48 to 0.96; P=0.03) and rs10273639 (hazard ratio, 0.69; 
95%CI, 0.49 to 0.98; P=0.04) were significantly associated with risk of developing pancreatitis in AALL0232 
cohort (supplemental page 8). 
Two previous studies have investigated SNPs associated to pancreatitis in children with ALL.  
Using different diagnostic criteria for pancreatitis and including controls with less than five weeks of 
asparaginase therapy, Liu et al. associated the rare variant (general population minor allele 
frequency=0.009%) rs199695765 in carboxypeptidase A2 encoding CPA2 (hazard ratio, 587; 95% CI, 66.8 to 
5166; P=9 x 10
-9
) with AAP
8
. We did not directly genotype this SNP, and none of the genotyped SNPs in the 
CPA2 region were in LD with rs199695765. Of 32 SNPs 10kb up- and downstream from CPA2, rs66839817 
(T>C, OR, 1.28; 95% CI, 1.03 to 1.57; P=0.02) showed the strongest association.  
In a NOPHO GWA study we previously associated the ULK2 variant rs281366 (P=5.8 x 10
-7
) and RGS6 variant 
rs17179470 (P=1.3 x 10
-6
) to be most associated to AAP
13
. Excluding cases and controls from the NOPHO 
study, we failed to validate these results in 184 cases and 712 controls. Both rs281366 and rs17179470 
were directly genotyped in this cohort with non-significant P-values, P=0.84 and P=0.32, respectively. 
 
Genotype-phenotype associations  
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Table 2 shows associations between PRSS1-PRSS2 genotype and amount of PEG-asparaginase given prior to 
AAP, days from PEG-asparaginase injection to AAP, complications to pancreatitis, and risk of a second AAP 
after re-exposure to asparaginase. The risk allele was not associated with number of PEG-asparaginase 
injections prior to AAP or time from injection of PEG-asparaginase to diagnosis of AAP. Furthermore, the 
risk of developing acute complications was not found to be associated to PRSS1-PRSS2 genotype (Table 2). 
In the Nordic subset of cases (n=92) and controls (n=1024) we found no association between PRSS1-PRSS2 
genotype and 5-year event free survival (supplemental figure 9; P=0.4). Out of 46 children who were re-
exposed to asparaginase, 17 (37%) developed a second AAP, although not statistically significant, the 
PRSS1-PRSS2 minor allele indicated the same protective effect as in the risk of initial AAP (OR, 0.49; 95% CI, 
0.15 to 1.41; P=0.20).  
 
Discussion 
This study is the first to find and validate variants in the PRSS1-PRSS2 locus associated to the risk of AAP in 
children with ALL. In doing so, we find that activation of trypsin within pancreatic acinar cells is a key 
initiating event in the pathogenesis of pancreatitis, regardless of the exposure i.e. alcohol, hyperlipidemia, 
or asparaginase. The role of trypsin activation in pancreatitis pathogenesis was long suspected, but 
underlying genetic susceptibility was not documented until 1996 when Whitcomb et al. documented 
mutations in the PRSS1 gene causing hereditary pancreatitis
29
, and later associated a common genetic 
variant in the PRSS1-PRSS2 locus (rs10273639) with risk of alcohol-related and sporadic pancreatitis
30
.  This 
association has recently been validated in larger European and Asian cohorts, and the haplotype has been 
studied in detail
31–33
. Rs10273639 is located 408 base pairs upstream from the translation initiation codon 
of cationic trypsinogen. A recent functional study has documented the proximal rs4726576 (C>A) variant 
(204 kb upstream from the translation initiation codon) to be driving the association
34
. The rs4726576 and 
the rs10273639 variants are in high LD (r
2 
> 99%) in European and Asian populations but have a r
2 
= 0.8 in 
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the African meta-population, and pinpointing the association driving the signal is thus of importance in the 
latter population. Sequencing the PRSS1-PRSS2 risk allele has not found disease-associated coding variants 
accounting for the pancreatitis association in GWA studies, however the risk allele [rs4726576; rs10273639] 
is an expressive quantitative trait locus for PRSS1 shown to elevate gene expression
30,34
. 
The activation of trypsinogen is mediated by cleavage of the N-terminus extension of cationic trypsinogen 
(a calcium binding site) to active trypsin. Higher levels of calcium has been shown to lead to trypsin 
activation, and with higher expression of trypsin as seen in patients with the [rs4726576; rs10273639] risk 
alleles, these patients are at higher risk of trypsin activation and pancreatitis
26
. In a study investigating the 
effect of asparaginase on pancreatic acinar cells, asparaginase evoked intracellular calcium release from the 
endoplasmic reticulum (ER) mediated by the protease-activated receptor 2 (Figure 3). This elevation in 
calcium levels in turn activated calcium release activated calcium (CRAC) channels further increasing 
intracellular calcium levels, leading to decreased ATP levels, trypsin activation and necrosis
35
. The 
pancreatitis causing mechanism seems independent of the anti-neoplastic effect of asparaginase, and drugs 
inhibiting CRAC channels could thus be used for AAP prevention during asparaginase therapy, not least in 
patients who after having had AAP are re-exposed to asparaginase, since these patients have a ~50% risk or 
developing a second episode of AAP
9,13
.   
Most significantly associated to AAP was the NFATC2 associated variant rs62228256. However, with no 
association found in the replication study and no association to pancreatitis found in adult studies on non-
asparaginase associated pancreatitis
26
, the association between NFATC2 and AAP seems to have low 
credibility. We were not able to associate the PRSS1-PRSS2 genotype to risk of AAP related complications, 
indicating that this allele only alters the risk of AAP, while the complications are a result of other factors. 
The validation of our PRSS1-PRSS2 top SNPs in the AALL0232 cohort strengthens the credibility of this 
results. The association was of similar effect size, but of borderline statistical significance, which may reflect 
three key issues: I) Diagnostic criteria differ between the cohorts, and cases are not completely 
comparable. II) Pancreatitis is strongly associated to asparaginase exposure, and it is a prerequisite that 
13 
 
 
included controls received a significant amount of asparaginase to reduce the risk of false negative 
controls. III) The validation cohorts were relatively small
36,37
.  
Our results however, need to be judged in light of their limitations. The association analyses were strongly 
influenced by individuals with CEU ethnicity, and we cannot determine the effects in non-CEU populations. 
Moreover, our results in the PRSS1-PRSS2 locus did not reach genome-wide significance with a p-value <5 x 
10
-8
. This highlights a challenge when doing GWAS in cohorts of limited size, as will often be the case in 
childhood ALL, and requires strategies for validation in independent and similar cohorts. In this present 
study, we attempted to limit the sample size challenge by improving the quality of phenotyping, collecting 
individual clinical data on AAP cases and including controls with documented completion of extensive 
asparaginase therapy.  
In conclusion, we find that children who develop AAP possess identical genetic risk variants as adults with 
non-asparaginase associated pancreatitis. This may allow future preventive measures for reduction of AAP.      
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Table 1 Top 30 single nucleotide polymorphisms 
 
SNP Chr Position 
Major>Minor 
allele 
MAF 
Cases 
MAF 
Controls 
OR (95%CI) P-value 
Gene 
(distance from gene) 
 
 rs62228256 20 50454447 C>T 0.07 0.02 3.75 (2.33-6.04) 5.18x10
-8
   
 
rs7270119 20 50436587 A>G 0.07 0.02 3.64 (2.28-5.8) 5.52x10
-8
  
 
 
rs16996276 20 50455925 A>C 0.07 0.02 3.64 (2.27-5.85) 8.64x10
-8
  
 
 
rs62228230 20 50445082 G>A 0.07 0.02 3.54 (2.23-5.63) 9.19x10
-8
  
 
 
rs934350 13 103589776 A>G 0.32 0.22 1.84 (1.47-2.3) 1.16x10
-7
  
 
 
rs170623 9 101984936 C>G 0.38 0.28 1.78 (1.42-2.22) 3.93x10
-7
 ALG2 (+0.69kb) & SEC61B (0) 
 
 
rs75245362 14 95990645 C>T 0.11 0.05 2.46 (1.73-3.51) 6.33x10
-7
 SCARNA13 (-9.05kb) & SNHG10 (-8.6kb) 
 
 
rs368819120 12 71747240 G>- 0.48 0.37 1.67 (1.35-2.06) 2.04x10
-6
  
 
 
rs4769201 13 22698015 A>G 0.04 0.01 4.66 (2.45-8.86) 2.67x10
-6
  
 
 
rs7851954 9 6796167 C>T 0.28 0.40 0.59 (0.47-0.74) 3.02x10
-6
 KDM4C (0) 
 
 
rs61734424 19 50747533 T>C 0.08 0.04 2.75 (1.8-4.2) 3.04x10
-6
 MYH14 (0) 
 
 
rs9912225 17 4680732 A>G 0.10 0.05 2.42 (1.67-3.5) 3.10x10
-6
 TM4SF5 (0) & VMO1 (-7.8kb) 
 
 
rs7155612 14 95976755 T>G 0.12 0.06 2.24 (1.6-3.15) 3.15x10
-6
  
 
 
rs2167730 8 78103417 T>C 0.24 0.34 0.57 (0.45-0.73) 3.69 x10
-6
  
 
 
rs80170196 19 50747159 C>T 0.08 0.04 2.73 (1.78-4.18) 3.77x10
-6
 MYH14 (0) 
 
 
rs62228228 20 50443845 G>A 0.06 0.02 3.15 (1.94-5.13) 3.80x10
-6
  
 
 
rs5010616 12 71748290 C>T 0.48 0.37 1.63 (1.32-2) 4.76x10
-6
  
 
 
rs12494164 3 164967758 A>C 0.23 0.14 1.77 (1.39-2.27) 4.83x10
-6
  
 
 
rs16848986 3 164979570 T>C 0.22 0.14 1.77 (1.38-2.26) 5.19x10
-6
  
 
 
rs34375180 12 71779640 G>A 0.49 0.38 1.61 (1.31-1.98) 5.53x10
-6
  
 
 
rs7139808 13 22693228 T>C 0.04 0.01 4.59 (2.38-8.87) 5.59x10
-6
  
 
 
rs12582343 12 71766297 A>G 0.48 0.38 1.62 (1.31-1.99) 5.90x10
-6
  
 
 
rs13228878 7 142473466 A>G 0.35 0.44 0.61 (0.5-0.76) 7.06x10
-6
 PRSS2 (-6.44kb) & PRSS3P2 (-5.29kb) 
 
 
rs6477109 9 6794938 C>T 0.29 0.40 0.61 (0.49-0.75) 7.64x10
-6
 KDM4C (0) 
 
 
rs74109922 13 103582300 A>G 0.12 0.06 2.13 (1.52-2.97) 1.03x10
-5
  
 
 
rs1505495 4 172973580 A>C 0.10 0.17 0.48 (0.34-0.66) 1.06x10
-5
 GALNTL6 (0) 
 
 
rs1791520 18 22118315 T>C 0.32 0.23 1.65 (1.32-2.07) 1.12x10
-5
  
 
 
rs10273639 7 142456928 C>T 0.35 0.44 0.62 (0.5-0.77) 1.13x10
-5
 PRSS1 (-0.4kb) 
 
 
rs4655107 1 23094454 G>A 0.13 0.24 0.53 (0.39-0.7) 1.16x10
-5
 EPHB2 (0) 
 
 
rs55634345 4 19846813 G>A 0.46 0.34 1.58 (1.29-1.94) 1.19x10
-5
  
 
Legend 
Top 30 SNPs most associated with AAP in in 244 cases and 1320 controls. The model used here includes covariates for age and genetic ancestry. SNPs 
were annotated to genes if ≤10kb upstream (-) or downstream (+) from transcription start site or transcription terminator, respectively. 
Abbreviations: SNP, single nucleotide polymorphism; Chr, chromosome; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval. 
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Table 2 Baseline characteristics, pancreatic enzyme levels and complications to pancreatitis in children according to the PRSS1-2 (rs13228878) 
genotype 
   
 
 
Homozygote for 
rs13228878_A risk allele 
 
Heterozygote for 
rs13228878_A risk allele 
 
Homozygote for 
rs13228878_G non- risk allele 
P 
 
  n=104 
 
 n=109 
 
 n=30   
 
Age 
(median; IQR) 
7.75 
(4–12.06) 
 
9.21 
(4.46–13.43) 
 
6.22 
(4.9–12.1) 
0.27 
 
 
Sex 
(% males) 
53% 
(55/104) 
 
55% 
(60/109) 
 
57% 
(17/30) 
0.92 
 
 
Total amylase at diagnosis of AAP (U/L) 
(median; IQR; n available data) 
397 
(263–673; n= 43) 
 
382 
(206–671; n=51) 
 
222 
(151–617; n=14) 
0.33 
 
 
Lipase at diagnosis of AAP (U/L)  
(median; IQR; n available data) 
1255 
(758–2140; n=39) 
 
1096 
(415–1754; n=48) 
 
867 
(193–2862; n=11) 
0.24 
 
 
Days from last PEG- 
asparaginase exposure to AAP  
(median; IQR) 
10.5 
(6–16; n=70) 
 
10.5 
(6–14; n=82) 
 
11 
(8–13.25; n=16) 
0.96 
 
 Number of PEG-asparaginase 
administrations prior to AAP 
(median; IQR) 
4 
(2–7; n=74) 
 
3 
(2–6; n=85) 
 
3.5 
(1.25–6.75; n=18) 
0.34 
 
 
Assisted Mechanical ventilation 
(yes (n)/available data (n)) 
5% 
(5/93)  
 
7% 
(7/101)  
 
0% 
0/26 
0.38 
 
 
Acute insulin therapy 
(yes (n)/available data (n)) 
21% 
(17/80) 
 
23% 
(20/87) 
 
18% 
(4/22) 
0.88 
 
 
Pseudocysts 
(yes (n)/available data (n)) 
25% 
(22/89) 
 
31% 
(31/100) 
 
8% 
(2/24) 
0.07 
 
 
Death 
(yes (n)/available data (n)) 
3% 
(3/93) 
 
1% 
(1/101) 
 
0% 
(0/27) 
0.38 
 
 
Legend 
Baseline characteristics, pancreatic enzyme levels and complications to pancreatitis according to rs13228878 genotype. Differences among groups are 
analyzed with Kruskal-Wallis rank sum test (continuous variables) and Chi-square test (categorical variables).
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Figure 1 
Manhattanplot 
Legend 
Manhattanplot showing SNPs associated with asparaginase-associated pancreatitis in 244 cases and 1320 
controls. The x axis represents genomic location, and the y axis represents the P value for the SNP's 
association calculated using logistic regression adjusting for age and ancestry. Genes previously associated 
to pancreatitis are marked in color. SNPs are annotated to genes based on genomic location (10 kb up- and 
downstream from transcription start site and transcription terminator, respectively. The human assembly 
GRCh37 was used for reference. 
 
Figure 2  
Regional  association plot of the PRSS1-2 locus on chromosome 7 
Legend 
Regional asssociation plot showing SNPs associated with asparaginase-associated pancreatitis in 244 cases 
and 1320 controls. The x axis represents genomic location, and the y axis represents the P value for the 
SNP's association calculated using logistic regression adjusting for age and ancestry. Rs13228878 (P=7.1 x 
10
-6
) is marked in purple and rs10273639 (P=1.1 x 10
-5
) in red. The color of the dots reflect linkage 
disequilibrium (LD) of the genotyped SNPs. LD is based on 1000 genomes European samples, November 
2014. The human assembly GRCh37 was used for reference.  
 
Figure 3 
Schematic diagram illustrating the effects of asparaginase on pancreatic acinar cells 
Legend 
Schematic drawing illustrating the likely effect of asparaginase (red triangle) on the protease-activated 
receptor 2 (PAR2) receptor, and how this leads to increased calcium (Ca
++
) efflux from the endoplasmic 
reticulum. This in turn leads to opening Ca
++
 release activated (CRAC) channels, further increasing 
intracellular calcium levels, reducing ATP levels and allowing activation of inactive trypsinogen to active 
trypsin. The diagram is heavily influenced by diagrams from Peng et al. Phil Trans Royal Soc, 2015 and 
Whitcomb et al. Nature Gen, 2012. 
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Supplemental	table	1	
Baseline	data,	acute	complications	and	risk	of	re-exposure	in	10	participating	trial	groups.	
	
	
Trial	group	name	
	
	
	
Trials	
	
	
	
	
N	
	
	
	
	
Male	sex	
	
	
	
	
Age	
(years)	
	
	
	
	
B-cell	
precursor	
ALL	
	
	
	
WBC	at	ALL	
diagnosis	
(109/L)		
	
	
	
	
Time	from	
ALL	diagnosis	
to	AAP	
(days)	
	
	
Assisted	
ventilation	
(yes	[n]/available	
data	[N])	
	
	
Acute	insulin	
therapy	
(yes	[n]/available	
data	[N])	
	
Pseudocysts	
(yes	
[n]/available	
data	[N])	
	
Second	
AAP	if	re-
exposed	
(yes	[n]/	
re-exposed	
patients	
[N])	
	
Death	
due	to	
AAP	(n)	
	
	
	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
Associazione	Italiana	
Ematologia	Oncologia	
Pediatrica	
AIEOP-BFM	ALL	
2009	 18	
61%	
(11/18)	
9.8	
(4.3–13.1)	
94%	
(16/17)	
10.7	(4.3–28)	
(n=17)	
117	(43–215)	
(n=16)	 13%	(2/15)	 13%	(2/15)	 21%	(3/14)	 0%	(0/1)	 2	 	
	 Berlin-Frankfurt-Münster	Austria	
AIEOP-BFM	ALL	
2009	 7	
86%	
(6/7)	
15.1	
(10.4–16.5)	
71%	
(5/7)	
11.6	(6.5–15)	
(n=7)	
55	(45–123)	
(n=7)	 0%	(0/6)	 0%	(0/7)	 14%	(1/7)	 33%	(1/3)	 0	 	
	 Berlin-Frankfurt-Münster	
ALL-BFM	2000	
AIEOP-BFM	ALL	
2009	
49	 55%	(27/49)	
9.7	
(5.4–14.7)	
76%	
(37/49)	
12.1	(3.4–
23.8)	
(n=49)	
37	(30–161)	
(n=49)	 8%	(4/49)	 17%	(8/48)	 20%	(9/44)	 25%	(2/8)	 1	 	
	 The	Cooperative	ALL	Study	Group	 CoALL	97/08-09	 4	
50%	
(2/4)	
10.1	
(8–12)	
100%	
(4/4)	
4.1	(3.1–5.7)	
(n=4)	
231	(159–
273)	
(n=3)	
0%	(0/1)	 0%	(0/1)	 0%	(0/1)	 0%	(0/2)	 0	 	
	 Czech	Republic	
ALL-BFM	2000	
ALL-IC-BFM	2002	
AIEOP-BFM	ALL	
2009	
4	 0%	(0/4)	
7.1	
(2.5–12.3)	
100%	
(4/4)	
25.5	(4.8–
98.8)	
(n=4)	
149.5	(72–
228)	
(n=4)	
0%	(0/4)	 0%	(0/4)	 25%	(1/4)	 0%	(0/1)	 0	 	
	 Dutch	Childhood	Oncology	Group	 DCOG-ALL10/11	 25	
44%	
(11/25)	
8.2	
(5.2–13.6)	
80%	
(20/25)	
8.1	(3.8–31.2)	
(n=24)	
203	(46–295)	
(n=25)	 12%	(3/25)	 30%	(7/23)	 28%	(7/25)	 50%	(2/4)	 1	 	
	 Israel	
INS	2010	
AIEOP-BFM	ALL	
2009	
10	 70%	(7/10)	
11.2	
(8.1–15.3)	
56%	
(5/9)	
41	(6.3–104)	
(n=9)	
38	(31–113)	
(n=9)	 0%	(0/9)	 22%	(2/9)	 33%	(3/9)	 0%	(0/1)	 0	 	
	 Nordic	Society	of	Pediatric	Haematology	and	Oncology	 NOPHO	ALL	2008	 92	
55%	
(51/92)	
6.3	
(3.4–10.9)	
86%	
(65/76)	
20.6	(6.5–50)	
(n=76)	
110	(75–144)	
(n=76)	 4%	(3/76)	 22%	(17/76)	 28%	(21/76)	
53%	
(10/19)	 0	 	
	 Taiwan	Pediatric	Oncology	Group	
TPOG-ALL-
97/2002/2013	 5	
60%	
(3/5)	
6.9	
(6.6–8.2)	
100%	
(5/5)	
26	(1.2–79.8)	
(n=5)	
34	(31–150)	
(n=5)	 0%	(0/5)	 50%	(2/4)	 40%	(2/5)	 50%	(1/2)	 0	 	
	 United	Kingdom	ALL	Working	Party	 UKALL2003	 30	
50%	
(15/30)	
9.4	
(4.7–13.3)	
83%	
(24/29)	
7.3	(3–41.1)	
(n=30)	
146	(82–225)	
(n=30)	 0%	(0/30)	 100%	(3/3)	 28%	(8/29)	 20%	(1/5)	 0	 	
	 10	Groups	 14	Trials	 244	 55%	(133/244)	
8.1	years	
(4.3––13.1)	
82%	
(185/225)	
15.3	(4–41)	
(n=225)	
99.5	(41–182)	
(n=224)	 5%	(12/220)	 22%	(41/190)	 26%	(55/214)	
37%	
(17/46)	 1·8%	(4/224)	
Legend	
Baseline	data,	acute	complications	and	risk	of	re-exposure	in	10	participating	trial	groups.	Data	are	n,	median	(IQR),	%(n/N),	unless	indicated	otherwise.	
*Number	of	re-exposed	patients	with	data	on	second	AAP.	
Note:	BCP	refers	to	percentage	with	B-cell	precursor	acute	lymphoblastic	leukemia,	the	remaining	group	had	T-cell	leukemia.	
Abbreviations:	AAP,	asparaginase-associated	pancreatitis;	IQR,	interquartile	range	(25th/75th	centiles);	BCP	ALL,	B-cell	precursor	acute	lymphoblastic	leukemia;	WBC,	
white	blood	cell	count.
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Supplemental	figure	1	
Pie	charts	showing	the	distribtution	of	cases	and	controls	according	to	trialgroup	
	
	
	
	
	
	
	
	
	
	
	
	
Legend	
Pie	charts	showing	the	distribution	of	244	AAP	cases	and	1320	controls	according	to	childhood	acute	lymphoblastic	leukemia	trial	group.	
Abbreviations:	AIEOP,	Associazione	Italiana	Ematologia	Oncologia	Pediatrica;	BFM,	Berlin-Frankfurt-Münster	(Germany)	;	BFM-Austria,	Berlin-
Frankfurt-Münster	Austria;	CoALL,	The	Cooperative	ALL	Study	Group	(Germany);	Czech,	Czech	Working	Group	for	Paediatric	Haematology;	
DCOG,	Dutch	Childhood	Oncology	Group;	DFCI,	Dana	Farber	Cancer	Institute	(US);	Israel,	Israeli	childhood	cancer	group;	NOPHO,	Nordic	Society	
of	Pediatric	Haematology	and	Oncology	(Denmark,	Estonia,	Finland,	Iceland,	Lithuania,	Norway,	Sweden);	TOPG,	Taiwan	Pediatric	Oncology	
Group;	UKALL,	United	Kingdom	ALL	Working	Party.	
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Supplemental	figure	2	
Quality	control	flowchart		
	
	
																			
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Legend	
Flow	diagram	illustrating	the	quality	control	of	individual	and	single	nucleotide	polymorphism	data.	
Assessed	for	eligibility																														
2631699	variants																																						
1895	individuals	(311	cases	1584	controls)	
Discordant	sex	in	geno	and	phenotypes	
(ntotal	=113;	ncases	=	34;	ncontrols	=79)		
Individuals	missing	>10%	of	variants																					
(ntotal	=81;	ncases	=15;	ncontrols=66)		
Excess	heterozygosity																																																
(ntotal	=20;	ncases	=	5;	ncontrols	=15)	
Relatedness	between	individuals																											
(ntotal	=97;	ncases=	7;	ncontrols	=90)	
	
2631699	variants																																						
1584	individuals	(250	cases	1334	controls)	
SNPs	missing	in	>2%	of	individuals		
(nvariants	=302644)		
Not	in	HW	equlibrium	
(nvariants	=1909)		
Minor	allele	frequency	
(nvariants	=898665)	
Difference	in	call	rate	between	cases	and	controls	
(nvariants	=6)	
Duplicated	variants		
(nvariants=26567)	
	
-			Individuals	missing	>3%	of	variants									
(ntotal=20;	ncases=6;	ncontrols=14)		
	
Study	cohort																																																			
1401908	variants																																																		
1564	individuals	(244	cases	1320	controls)	
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Supplemental	figure	3	
Multidimensional	scaling	plots	of	genetic	ancestry	in	study	population	
	
Legend	
Multidimensional	scaling	plots	plot	of	genetic	ancestry	of	AAP	cases,	controls	and	HAPMAP	controls	for	
reference.	Abbreviations:	CEU,	Utah	residents	with	Northern	and	Western	European	ancestry;	CHB,	Han	
Chinese	in	Beijing,	China;	JPT,	Japanese	in	Tokyo,	Japan;	YRI,	Yoruba	in	Ibadan,	Nigeria.
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Supplemental	figure	4	
Quartile-quartile	plot	
	
Legend	
Quartile-quartile	plot	showing	the	expected	vs	the	observed	p-values	in	the	cohort	of	244	cases	and	
1320	controls.	The	logistic	regression	analysis	was	adjusted	for	age	and	genetic	ancestry,	with	a	lambda	
of	1.02	there	was	no	evidence	of	population	substructure.	
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Description	of	validation	cohort	
Replication	of	results	in	the	Children’s	Oncology	Group	AALL0232	cohort	
All	data	is	provided	from	Liu	et	al.	“Clinical	and	Genetic	Risk	Factors	for	Acute	Pancreatitis	in	
Patients	With	Acute	Lymphoblastic	Leukemia”;	Journal	of	Clinical	Oncology	2016.	
The	AALL0232	trial	was	used	for	validation.	This	cohort	constitutes	the	largest	cohort,	with	significant	
duration	of	asparaginase	treatment	(~16	weeks)	previously	published	(Liu	et	al.	Journal	of	Clinical	
Oncology,	2016).		The	trial	included	3058	patients,	out	of	which	genotyping	data	was	available	in	76	
cases	diagnosed	using	National	Cancer	Institute’s	Common	Terminology	Criteria	for	Adverse	Events,	and	
2577	controls.	The	cohort	was	included,	in	the	only	other	GWAS	published	on	pancreatitis	in	children	
with	ALL1.	The	AALL0232	cohort	was	genotyped	on	the	Affymetrix	Genome-Wide	Human	SNP	6.0	(or	
GeneChip	Human	Mapping	500K)	Array,	and	linkage	disequilibrium	(LD)	between	SNPs	in	the	
investigation	and	validation	study	was	assessed	by	the	National	Cancer	Institute	LDassoc	tool.		
Diagnostic	criteria	for	pancreatitis	
National	Cancer	Institute’s	Common	Terminology	Criteria	for	Adverse	Events	for	Pancreatitis	
(https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf)	grade	2-4	
were	included	as	cases	in	the	analysis:	
Adverse	Event	 Short	Name	 Grade	1	 Grade	2	 Grade	3	 Grade	4	 Grade	5	
Pancreatitis	 Pancreatitis	 Asymptomatic,	
enzyme	
elevation	and/or	
radiographic	
findings	
Symptomatic,	
medical	
intervention	
indicated	
Interventional	
radiology	or	
operative	
intervention	
indicated	
Life-threatening	
consequences	
(e.g.,	circulatory	
failure,	
hemorrhage,	
sepsis)	
Death	
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Asparaginase	exposure	in	protocol	AALL0232	
	
Induction	 Extended	Inductiona	 Consolidation	
Interim	Maintenance	
and	Delayed	
Intensification	
Total	ASP	doseb	U/m2	
(excluding	Extended	
induction)	
Total	ASP	weeksc	
(excluding	Extended	
induction)	
N	(%)	of	
patients	
developing	
pancreatitis	
PEG	2500	
U/m2	x1	
PEG	2500	
U/m2	x1	
PEG	2500	
U/m2	×	2	
DH/PH:	PEG	2500	U/m2	×	
2	(single	IM/DI)	or	PEG	
2500	U/m2	×	6	(double	
IM/DI)	
	
	
250.000–
4500000	
	
10–18	 32/1359	
(2.4%)	
DC/PC:	PEG	2500	U/m2	×	
4	(single	IM/DI)	or	×	6	
(double	IM/DI)	
350.000–
550,000	
14–22	 44/1294	
(3.4%)	
	
All	asparaginase	was	given	intramuscularly.	aDepends	on	patients’	bone	marrow	blast	percent	during	
induction	or	minimal	residual	disease	(MRD)	status	at	the	end	of	Induction.	bTotal	dose	and	ctotal	weeks	
of	PEG-asparaginase	during	therapy,	excluded	the	extended	Induction.	Abbreviations:	ASP,	
asparaginase;	PEG,	pegylated;	DH/PH,	dexamethasone/prednisone	during	induction	therapy	and	high-
dose	methotrexate/leucovorin	during	the	first	interim	maintenance;	DC/PC,	dexamethasone/prednisone	
during	induction	therapy	and	escalating	methotrexate/leucovorin	during	the	first	interim	maintenance.	
	
Baseline	data	in	2653	patients	included	in	the	AALL0232	genome-wide	association	study	cohort	
	
	
	
	
	
	
	
	
	
	
	
	
	
		 ALL0232	(n=2653)	
	
	 	
	 Age	 		 	
	 1−10	years	old	 907	(34.2%)	 	
	 10−30	years	old	 1746	(65.8%)	 	
	 Gender	 		 	
	 Male	 1468	(55.3%)	 	
	 Female	 1185	(44.7%)	 	
	 Race	 		 	
	 White	 1455	(54.8%)	 	
	 Black	 134	(5.1%)	 	
	 Hispanic	 710	(26.8%)	 	
	 Asian	 60	(2.3%)	 	
	 Other	 294	(11.1%)	 	
	 Immunophenotype	 		 	
	 B-lineage	 2653	(100%)	 	
	 T-lineage	 0	(0%)	 	
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Association	analysis	
Time-dependent	analysis	(Cox	proportional	hazards	regression)	was	performed	adjusting	for	age	and	
ancestry.	
Legend	
The	table	shows	results	from	the	replication	study.		
	
Genotypes	
rs13228878	 	 	
	
	 CC		 CT		 TT	
	
	 Controls	 585	 1227	 765	 	
	 Cases	with	
pancreatitis	 11	 35	 30	
	
	 %	pan	 0·02	 0·03	 0·04	 	
Legend	
Genotype	of	rs13228878.	The	table	shows	the	rs13228878	genotype	in	cases	with	pancreatitis	and	
controls	without	pancreatitis.		
	
Genotypes	
rs10273639	 	 	
	
	 CC		 CT		 TT	
	
	 Controls	 561	 1253	 763	 	
	 Cases	with	
pancreatitis	 11	 35	 30	
	
	 %	pan	 0·02	 0·03	 0·04	 	
	
Legend	
Genotype	of	rs10273639.	The	table	shows	the	rs10273639	genotype	in	cases	with	pancreatitis	and	
controls	without	pancreatitis.	
	
	
AALL0232	(high	asparaginase	dose)	All	patients.	N=2653,	76	cases	
	
	
	
Major>minor	allele	 HR	(95%	CI)	 P	
	 rs13228878	 A>G	 0.68	(0.48−0.96)	 0.03	
	 rs10273639	 C>T	 0.69	(0.49–0.98)	 0.04	
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Replication	of	results	in	the	Dana	Farber	Cancer	Institute	consortium	87−01,	91−01,	95−01	and	00−01	
ALL	cohort	
A	cohort	of	ALL	children	recruited	from	the	Dana	Farber	Cancer	Institute	(DFCI)	were	used	for	the	
validation	of	the	rs62228256	polymorphism	on	20q13.2.	Patients	were	treated	according	to	DFCI	ALL	
Consortium	protocols	DFCI	87-01,	91-01,	95-01,	or	00-01	between	January,	1987	and	July,	2005	
receiving	variable	asparaginase	exposure2–4.	This	cohort	is	further	referred	to	as	DFCI.		Genotyping	was	
performed	on	a	total	of	318	patients,	out	of	which	33	were	cases	of	pancreatitis	diagnosed	according	to	
the	CTCAE	criteria	and	285	were	controls.	Cases	were	identified	by	retrospective	evaluation	of	medical	
charts.	This	cohort	was	genotyped	by	allele-specific	oligonucleotide	hybridization	as	described	
elsewhere.5		Briefly,	while	in	DFCI	95-01	and	DFCI	00-01,	one	dose	of	asparaginase	was	administered	
during	remission	induction,	asparaginase	was	administered	for	20	to	30	consecutive	weeks	during	
consolidation	phase	in	all	protocols.	
	
Asparaginase	exposure	in	Dana	Farber	Cancer	Institute	protocols	
Asparaginase	according	to	protocol	
Induction	(4	weeks)	
Protocol	87-01	 E.	coli,	Erwinia	or	PEG	ASP	×	1	dose	(randomized;	investigational	window;	5	days	pre-day	0)	
Protocol	91-01	 None	
Protocol	95-01	 E.	coli	or	Erwinia	ASP	25 000 IU/m2	×	1	dose	(randomized;	day	4)	
Protocol	00-01	 E.	coli	ASP	25,000	IU/m2	IM	×	1	dose	
	 	
Intensification	(20–30	weeks)	every	3-week	cycle	
Protocol	87-01	 E.	coli	ASP	25 000 IU/m2	weekly	
Protocol	91-01	 Randomized	to	E.	coli	ASP	25 000 IU/m
2	weekly	or	PEG	ASP	
2500 IU/m2	every	2	weeks	
Protocol	95-01	 Randomized	to	E.	coli	ASP	25 000 IU/m
2	weekly	or	Erwinia	ASP	
25 000 IU/m2	weekly	
Protocol	00-01	 Randomized	to	fixed	dosing	of	E.	coli	ASP	(based	upon	BSA)	and	individualized	dosing	(based	upon	NSAA	every	3	weeks)	
	
Abbreviations:	ASP,	asparaginase;	PEG,	pegylated;	BSA,	body	surface	area;	NSAA,	nadir	serum	
asparaginase	activity.	
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Baseline	data	in	318	patients	included	in	the	Dana	Farber	Cancer	Institute	cohort	
	
	
	
	
	
	
	
	
	
	
	
	
	
Association	analysis	
Binary	logistic	regression	analysis	was	performed	adjusting	for	age.	
	
Legend	
The	table	shows	results	from	the	replication	study	of	rs62228256.		
	 	
	
		 Dana	Farber	Cancer	Institute	Cohort	(n=318)	
	
	 	
	 Age	 		 	
	 1−10	years	old	 254	(79,9%)	 	
	 10−18	years	old	 64	(20,1%)	 	
	 Gender	 		 	
	 Male	 167	(52,5%)	 	
	 Female	 151	(47,5%)	 	
	 Immunophenotype	 		 	
	 B-lineage	 294	(92.5%)	 	
	 T-lineage	 24	(7.5%)	 	
	 Source	of	ASP	 		 	
	 Native	E.	Coli	 289	(90,9%)	 	
	 Erwinia	 29	(9,1%)	 	
	 DFCI	protocol	 		 	
	 00-01	 125	(39,3%)	 	
	 95-01	 122	(38,4%)	 	
	 91-01	 55	(17,3%)	 	
	 87-01	 16	(5%)	 	
	
DFCI	ALL	cohort.	N=318,	33	cases	
	
	
	
Major>minor	allele	 OR	(95%	CI)	 P	
	 	
rs62228256	
	
C>T	
	
1.19	(0.35–4.03)	
	
0.77	
11	
	
Genotypes	
rs62228256	
	
	 CC		 CT		 TT	
	
	 Controls	 264	 20	 1	 	
	 Cases	with	
pancreatitis	 30	 3	 0	
	
	 %	pan	 0·10	 0·13	 0	 	
	
Legend	
Genotype	of	rs62228256.	The	table	shows	the	rs62228256	genotype	in	cases	with	pancreatitis	and	
controls	without	pancreatitis.		
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Regional		association	plot	of	the	PRSS1	and	PRSS2	loci	on	chromosome	7	in	AALL0232	
	
	
Legend	
Regional	asssociation	plot	showing	SNPs	associated	with	asparaginase-associated	pancreatitis	in	76	
cases	and	2570	controls.	The	x	axis	represents	genomic	location,	and	the	y	axis	represents	the	P	value	
for	the	SNP's	association	calculated	using	logistic	regression	adjusting	for	age	and	ancestry.	The	color	of	
the	dots	reflects	the	linkage	disequilibrium	of	the	genotyped	SNPs	and	rs13228878.	LD	is	based	on	1000	
genomes	European	CEU	samples,	November	2014.	The	human	assembly	GRCh37	was	used	for	reference.		
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Supplemental	figure	5	
Rs62228256	and	Nuclear	factor	of	activated	T	cells	(NFATC2)		
	
	
	
Legend	
NFATC2	gene	expression	according	to	rs62228256	genotype.	Homo	Ref	refers	to	the	major	C	allele,	
Homo	Alt	refers	to	the	minor	T	allele.	The	difference	between	groups	is	statistically	significant,	P=0.045.	
Plot	is	downloaded	from	www.gtexportal.org/home/.	
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Supplemental	figure	6	
Multidimensional	scaling	plots	of	genetic	ancestry	from	CEU	cohort	
	
Legend	
Multidimensional	scaling	plots	plot	of	genetic	ancestry	in	AAP	cases	and	controls	from	the	CEU	
population.	Defined	as	individuals	>16	standard	deviations	away	from	the	HapMap-defined	CEU	
(Northern	and	Western	European)	centroid	mean.
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Supplemental	figure	7	
Quartile-quartile	plot	of	CEU	cohort	
	
	
Legend	
Quartile-quartile	plot	showing	the	expected	vs	the	observed	p-values	in	the	CEU	cohort	of	205	cases	and	
1185	controls.	The	logistic	regression	analysis	was	adjusted	for	age	and	genetic	ancestry,	with	a	lambda	
of	1.02	there	was	no	evidence	of	population	substructure.	
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Supplemental	figure	8	
Manhattanplot	of	CEU	cohort	
	
Legend	
Manhattanplot	showing	SNPs	associated	with	asparaginase-associated	pancreatitis	in	205	cases	and	1185	controls	in	the	CEU	cohort.	The	x	axis	
represents	genomic	location,	and	the	y	axis	represents	the	P	value	for	the	SNP's	association	calculated	using	logistic	regression	adjusting	for	age	
and	ancestry.	Genes	previously	associated	to	pancreatitis	are	marked	in	color.	SNPs	are	annotated	to	genes	based	on	genomic	location	(10	kb	
up-	and	downstream	from	transcription	start	site	and	transcription	terminator,	respectively.	The	human	assembly	GRCh37	was	used	for	
reference.	
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Supplemental	table	2	
Top	SNPs	in	genes	previously	associated	with	risk	of	pancreatitis	in	CEU	cohort	
	 Gene	 CHR	 BP	 SNP	 Major>minor	allele	 MAF	Cases	
MAF	
Controls	 OR	(95%CI)	 P	 	
	 CASR	 3	 121913370	 rs937627	 G>T	 0.17	 0.23	 0.73	(0.55−0.97)	 0.03	 	
	 CASR	 3	 121908434	 rs4678029	 T>C	 0.17	 0.23	 0.73	(0.55−0.97)	 0.03	 	
	 CASR	 3	 121919740	 rs16832787	 G>A	 0.17	 0.23	 0.73	(0.55−0.97)	 0.03	 	
	 CASR	 3	 121936323	 rs13320637	 G>A	 0.22	 0.27	 0.76	(0.59−0.98)	 0.04	 	
	 CASR	 3	 121936370	 rs13327652	 A>G	 0.22	 0.27	 0.76	(0.59−0.99)	 0.04	 	
	 CFTR	 7	 117145102	 rs56296320	 T>C	 0.007	 0.02	 0.34	(0.11−1.11)	 0.07	 	
	 CFTR	 7	 117178754	 rs17449197	 A>G	 0.11	 0.14	 0.79	(0.57−1.09)	 0.15	 	
	 CFTR	 7	 117119183	 rs4148682	 T>G	 0.1	 0.08	 1.26	(0.88−1.82)	 0.21	 	
	 CFTR	 7	 117181509	 rs4148703	 G>A	 0.1	 0.09	 1.26	(0.87−1.81)	 0.22	 	
	 CFTR	 7	 117219835	 rs1469486	 C>T	 0.13	 0.12	 1.22	(0.88−1.68)	 0.23	 	
	 CLDN2	 23	 106134938	 rs12853674	 C>T	 0.12	 0.08	 1.67	(1.11−2.53)	 0.01	 	
	 CLDN2	 23	 106140325	 rs4409525	 G>A	 0.34	 0.28	 1.4	(1.06−1.83)	 0.02	 	
	 CLDN2	 23	 106160702	 rs12008279	 A>G	 0.51	 0.44	 1.31	(1.02−1.69)	 0.03	 	
	 CLDN2	 23	 106183670	 rs12014762	 C>T	 0.22	 0.17	 1.32	(0.97−1.8)	 0.07	 	
	 CLDN2	 23	 106136910	 rs5962770	 T>C	 0.28	 0.3	 0.98	(0.74−1.3)	 0.87	 	
	 CPA1	 7	 130037805	 rs73152870	 A>G	 0.039	 0.02	 1.67	(0.92−3.01)	 0.09	 	
	 CPA1	 7	 130018863	 rs10954269	 C>T	 0.09	 0.1	 0.77	(0.53−1.12)	 0.18	 	
	 CPA1	 7	 130033556	 rs17389898	 T>C	 0.07	 0.05	 1.36	(0.87−2.12)	 0.18	 	
	 CPA1	 7	 130019491	 rs13226219	 T>C	 0.09	 0.1	 0.79	(0.54−1.15)	 0.21	 	
	 CPA1	 7	 130028089	 rs17330508	 C>T	 0.037	 0.03	 1.3	(0.71−2.36)	 0.39	 	
	 CTRB1-2	 16	 75254970	 rs57833904	 C>T	 0.015	 0.005	 2.56	(0.92−7.16)	 0.07	 	
	 CTRB1-2	 16	 75230638	 rs1019537	 C>T	 0.13	 0.15	 0.74	(0.54−1.03)	 0.07	 	
	 CTRB1-2	 16	 75230739	 rs1019539	 C>T	 0.12	 0.15	 0.74	(0.54−1.03)	 0.08	 	
	 CTRB1-2	 16	 75230230	 rs1559362	 T>C	 0.32	 0.34	 0.85	(0.67−1.07)	 0.16	 	
	 CTRB1-2	 16	 75263661	 rs7190458	 G>A	 0.06	 0.05	 1.39	(0.87−2.24)	 0.17	 	
	 CTRC	 1	 15758963	 rs35994710	 C>T	 0.16	 0.23	 0.63	(0.47−0.84)	 0.002	 	
	 CTRC	 1	 15768304	 rs10436957	 G>A	 0.17	 0.24	 0.65	(0.49−0.86)	 0.003	 	
	 CTRC	 1	 15757666	 rs10754889	 G>A	 0.30	 0.36	 0.71	(0.56−0.9)	 0.004	 	
	 CTRC	 1	 15760092	 rs7541863	 C>T	 0.31	 0.37	 0.71	(0.56−0.9)	 0.005	 	
	 CTRC	 1	 15763340	 rs6693417	 A>G	 0.33	 0.4	 0.72	(0.57−0.91)	 0.005	 	
	 PRSS1-2	 7	 142473466	 rs13228878	 A>G	 0.31	 0.42	 0.6	(0.48−0.76)	 2.1	x	10−5	 	
	 PRSS1-2	 7	 142456928	 rs10273639	 C>T	 0.32	 0.43	 0.62	(0.49−0.78)	 3.8	x	10−5	 	
	 PRSS1-2	 7	 142487836	 rs2734222	 C>T	 0.38	 0.47	 0.66	(0.53−0.82)	 0.0002	 	
	 PRSS1-2	 7	 142455538	 rs3757377	 G>A	 0.3	 0.39	 0.65(0.52−0.83)	 0.0004	 	
	 PRSS1-2	 7	 142488688	 rs2734224	 G>A	 0.39	 0.47	 0.7(0.56−0.87)	 0.001	 	
	 SPINK1	 5	 147207678	 rs17107315	 A>G	 0.02	 0.01	 2.78(1.29−5.97)	 0.009	 	
	 SPINK1	 5	 147220041	 rs4705045	 T>G	 0.11	 0.14	 0.73(0.52−1.02)	 0.07	 	
	 SPINK1	 5	 147211393	 rs4705203	 A>G	 0.12	 0.14	 0.78(0.56−1.08)	 0.13	 	
	 SPINK1	 5	 147204192	 rs11319	 C>T	 0.05	 0.05	 1.35(0.82−2.2)	 0.23	 	
	 SPINK1	 5	 147205839	 rs17703305	 G>T	 0.46	 0.43	 1.13(0.91−1.41)	 0.27	 	
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Legend	
Top-five	SNPs	associated	with	asparaginase-associated	pancreatitis	in	the	CEU	cohort	of	205	cases	and	
1185	controls.	SNPs	were	annotated	to	genes	if	≤10kb	upstream	or	downstream	from	transcription	start	
site	or	transcription	terminator,	respectively.	Genefunctions	below	are	defined	by	Genecards	
(www.genecards.org)	and	UniPort	(www.uniprot.org).	
Abbreviations:	SNP,	single	nucleotide	polymorphism;	Chr,	chromosome;	MAF,	minor	allele	frequency;	
OR,	odds	ratio;	CI,	confidence	interval;	CASR,	calcium-sensing	receptor	(G	protein-coupled	receptor,	
small	changes	in	circulating	calcium	concentration	are	monitored	affecting	intracellular	signaling	
pathways);	CFTR,	cystic	fibrosis	transmembrane	conductance	regulator	(cAMP-regulated	cell	channel,	
conducting	chloride	and	thiocyanate	ions	across	epithelial	membranes);	CLDN2,	claudin-2	(Major	
integral	membrane	protein	localized	exclusively	at	tight	junctions);	CPA1:	Carboxypeptidase	A1	
(Member	of	the	serine	protease	family,	A1	form	of	the	pancreatic	procarboxypeptidase	produced	in	
pancreatic	acinar	cells,	preferentially	cleaves	C-terminal	branched-chain	and	aromatic	amino	acids	from	
dietary	proteins);	CTRB1-2m,	chymotrypsin	B1-B2	(member	of	the	serine	protease	family	of	enzymes,	
regulating	activation	and	degradation	of	trypsinogens	and	procarboxypeptidases	by	targeting	specific	
cleavage	sites	within	their	zymogen	precursors);	CTRC:	chymotrypsin	C	(serum	calcium-decreasing	factor	
with	chymotrypsin-like	protease	activity,	regulating	activation	and	degradation	of	trypsinogens	and	
procarboxypeptidases	by	targeting	specific	cleavage	sites	within	their	zymogen	precursors);	PRSS1-2,	
protease,	serine,	2	(encoding	for	cationic	and	anionic	trypsinogen);	SPINK1,	serine	peptidase	inhibitor,	
kazal	type	1	(Prevention	of	trypsin-catalyzed	premature	activation	of	zymogens	within	the	pancreas	and	
the	pancreatic	duct).			
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Supplemental	table	3	
Top	SNPs	in	genes	previously	associated	with	risk	of	pancreatitis	in	the	total	cohort	
	
	 Gene	 CHR	 BP	 SNP	 Major>minor	allele	
MAF	
Cases	
MAF	
Controls	 OR	(95%	CI)	 P	 	
	 CASR	 3	 121965199	 rs9859381	 G>T	 0.18	 0.13	 1.3	(0.99-1.71)	 0.06	 	
	 CASR	 3	 121913370	 rs937627	 G>T	 0.19	 0.23	 0.78	(0.61-1.01)	 0.063	 	
	 CASR	 3	 121919740	 rs16832787	 G>A	 0.19	 0.23	 0.78	(0.61-1.01)	 0.064	 	
	 CASR	 3	 121908434	 rs4678029	 T>C	 0.19	 0.23	 0.79	(0.61-1.02)	 0.067	 	
	 CASR	 3	 121971512	 rs937625	 T>G	 0.11	 0.08	 1.37	(0.98-1.92)	 0.068	 	
	 CFTR	 7	 117145102	 rs56296320	 T>C	 0.01	 0.02	 0.3	(0.09-0.97)	 0.044	 	
	 CFTR	 7	 117178754	 rs17449197	 A>G	 0.11	 0.14	 0.77	(0.56-1.04)	 0.09	 	
	 CFTR	 7	 117181509	 rs4148703	 G>A	 0.12	 0.09	 1.3	(0.94-1.79)	 0.11	 	
	 CFTR	 7	 117119183	 rs4148682	 T>G	 0.12	 0.09	 1.28	(0.92-1.76)	 0.14	 	
	 CFTR	 7	 117279147	 rs6466615	 G>A	 0.01	 0.01	 0.4	(0.12-1.39)	 0.15	 	
	 CLDN2	 X	 106134938	 rs12853674	 C>T	 0.11	 0.08	 1.71	(1.16-2.52)	 0.007	 	
	 CLDN2	 X	 106140325	 rs4409525	 G>A	 0.34	 0.28	 1.35	(1.05-1.73)	 0.02	 	
	 CLDN2	 X	 106160702	 rs12008279	 A>G	 0.53	 0.45	 1.28	(1.01-1.62)	 0.04	 	
	 CLDN2	 X	 106183670	 rs12014762	 C>T	 0.21	 0.17	 1.3	(0.97-1.74)	 0.08	 	
	 CLDN2	 X	 106136910	 rs5962770	 T>C	 0.26	 0.29	 0.99	(0.76-1.3)	 0.1	 	
	 CPA1	 7	 130037805	 rs73152870	 A>G	 0.04	 0.02	 1.88	(1.08-3.27)	 0.03	 	
	 CPA1	 7	 130028089	 rs17330508	 C>T	 0.04	 0.03	 1.59	(0.92-2.74)	 0.1	 	
	 CPA1	 7	 130018863	 rs10954269	 C>T	 0.09	 0.10	 0.75	(0.53-1.06)	 0.1	 	
	 CPA1	 7	 130019491	 rs13226219	 T>C	 0.10	 0.11	 0.77	(0.55-1.09)	 0.14	 	
	 CPA1	 7	 130033556	 rs17389898	 T>C	 0.07	 0.05	 1.36	(0.89-2.06)	 0.16	 	
	 CTRB1-2	 16	 75252306	 rs8056797	 G>T	 0.03	 0.01	 2.63	(1.22-5.69)	 0.01	 	
	 CTRB1-2	 16	 75254970	 rs57833904	 C>T	 0.03	 0.01	 2.46	(1.17-5.16)	 0.02	 	
	 CTRB1-2	 16	 75230638	 rs1019537	 C>T	 0.12	 0.14	 0.74	(0.54-1)	 0.05	 	
	 CTRB1-2	 16	 75230739	 rs1019539	 C>T	 0.12	 0.14	 0.75	(0.55-1.01)	 0.06	 	
	 CTRB1-2	 16	 75263661	 rs7190458	 G>A	 0.06	 0.04	 1.45	(0.93-2.26)	 0.1	 	
	 CTRC	 1	 15768304	 rs10436957	 G>A	 0.17	 0.23	 0.69	(0.53-0.89)	 0.005	 	
	 CTRC	 1	 15758963	 rs35994710	 C>T	 0.16	 0.22	 0.68	(0.52-0.89)	 0.005	 	
	 CTRC	 1	 15760092	 rs7541863	 C>T	 0.33	 0.38	 0.76	(0.61-0.94)	 0.01	 	
	 CTRC	 1	 15763340	 rs6693417	 A>G	 0.35	 0.41	 0.77	(0.62-0.95)	 0.01	 	
	 CTRC	 1	 15757666	 rs10754889	 G>A	 0.32	 0.37	 0.77	(0.62-0.96)	 0.02	 	
	 PRSS1-2	 7	 142473466	 rs13228878	 A>G	 0.35	 0.44	 0.61	(0.5-0.76)	 7.1	x	10-6	 	
	 PRSS1-2	 7	 142456928	 rs10273639	 C>T	 0.35	 0.44	 0.62	(0.5-0.77)	 1.1	x	10-5	 	
	 PRSS1-2	 7	 142487836	 rs2734222	 C>T	 0.40	 0.48	 0.65	(0.53-0.8)	 4.8	x	10-5	 	
	 PRSS1-2	 7	 142488688	 rs2734224	 G>A	 0.41	 0.49	 0.68	(0.55-0.83)	 0.0002	 	
	 PRSS1-2	 7	 142455538	 rs3757377	 G>A	 0.33	 0.40	 0.67	(0.54-0.83)	 0.0002	 	
	 SPINK1	 5	 147207678	 rs17107315	 A>G	 0.02	 0.01	 2.86	(1.4-5.85)	 0.004	 	
	 SPINK1	 5	 147220041	 rs4705045	 T>G	 0.12	 0.14	 0.73	(0.54-1)	 0.05	 	
	 SPINK1	 5	 147215120	 rs4705204	 T>G	 0.23	 0.18	 1.23	(0.96-1.57)	 0.1	 	
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	 SPINK1	 5	 147211393	 rs4705203	 A>G	 0.13	 0.15	 0.78	(0.58-1.06)	 0.11	 	
	 SPINK1	 5	 147205839	 rs17703305	 G>T	 0.46	 0.42	 1.18	(0.96-1.44)	 0.12	 	
	
Legend	
Top-five	SNPs	associated	with	asparaginase-associated	pancreatitis	in	244	cases	and	1320	controls.	SNPs	
were	annotated	to	genes	if	≤10kb	upstream	or	downstream	from	transcription	start	site	or	transcription	
terminator,	respectively.	SNPs	and	genes	were	identified	from	litterature	search	(see	methods	section),	
genefunctions	are	defined	by	Genecards	(www.genecards.org)	and	UniPort	(www.uniprot.org).	
Abbreviations:	SNP,	single	nucleotide	polymorphism;	Chr,	chromosome;	MAF,	minor	allele	frequency;	
OR,	odds	ratio;	CI,	confidence	interval;	CASR,	calcium-sensing	receptor	(G	protein-coupled	receptor,	
small	changes	in	circulating	calcium	concentration	are	monitored	affecting	intracellular	signaling	
pathways);	CFTR,	cystic	fibrosis	transmembrane	conductance	regulator	(cAMP-regulated	cell	channel,	
conducting	chloride	and	thiocyanate	ions	across	epithelial	membranes);	CLDN2,	claudin-2	(Major	
integral	membrane	protein	localized	exclusively	at	tight	junctions);	CPA1:	Carboxypeptidase	A1	
(Member	of	the	serine	protease	family,	A1	form	of	the	pancreatic	procarboxypeptidase	produced	in	
pancreatic	acinar	cells,	preferentially	cleaves	C-terminal	branched-chain	and	aromatic	amino	acids	from	
dietary	proteins);	CTRB1-2,	chymotrypsin	B1-B2	(member	of	the	serine	protease	family	of	enzymes,	
regulating	activation	and	degradation	of	trypsinogens	and	procarboxypeptidases	by	targeting	specific	
cleavage	sites	within	their	zymogen	precursors);	CTRC:	chymotrypsin	C	(serum	calcium-decreasing	factor	
with	chymotrypsin-like	protease	activity,	regulating	activation	and	degradation	of	trypsinogens	and	
procarboxypeptidases	by	targeting	specific	cleavage	sites	within	their	zymogen	precursors);	PRSS1-2,	
protease,	serine,	2	(encoding	for	cationic	and	anionic	trypsinogen);	SPINK1,	serine	peptidase	inhibitor,	
kazal	type	1	(Prevention	of	trypsin-catalyzed	premature	activation	of	zymogens	within	the	pancreas	and	
the	pancreatic	duct).			
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Supplemental	figure	9	
5-year	event	free	survival	according	to	PRSS1-PRSS2	genotype	
	
Legend	
Five-year	event	free	survival	in	the	Nordic	subset	of	cases	(n=92)	and	controls	(n=1024)	grouped	
according	to	PRSS1-2	genotype	(rs13228878).	Event	was	defined	as	death,	relapse	or	second	malignant	
neoplasm.	No	difference	in	five-years	event-free	survival	was	found	using	the	2-sided	log-rank	test	
(P=0.4).	See	through	colors	denote	95%	confidence	intervals.		
